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Mutations in DPAGT1 are a newly recognised cause of congenital myasthenic syndrome. DPAGT1 encodes an early component of
the N-linked glycosylation pathway. Initially mutations in DPAGT1 have been associated with the onset of the severe multisystem
disorder – congenital disorder of glycosylation type 1J. However, recently it was established that certain mutations in this gene can
cause symptoms restricted to muscle weakness resulting from defective neuromuscular transmission. We report four cases from a
large Iranian pedigree with prominent limb-girdle weakness and minimal craniobulbar symptoms who harbour a novel mutation in
DPAGT1, c.652C>T, p.Arg218Trp. This myasthenic syndrome may mimic myopathic disorders and is likely under-diagnosed.
 2013 Elsevier B.V.
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Open access under CC BY license.1. Introduction
The congenital myasthenic syndromes (CMS) constitute
a group of rare genetic disorders that result in impaired
synaptic transmission at the neuromuscular junction. The
number of genes shown to harbour mutations that
underlie CMS continues to grow with at least 16 described
[1,2]. Whereas many of the CMS involve mutations in
proteins with well-deﬁned functions at the neuromuscular
junction, the two most recently identiﬁed causes of CMS
are mutations in GFPT1 [3] and DPAGT1 [4] both of
which encode ubiquitously expressed proteins. DPAGT1
encodes dolichyl-phosphate (UDP-N-acetylglucosamine)0960-8966  2013 Elsevier B.V.
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Open access under CC BY license.N-acetylglucosaminephosphotransferase 1, an enzyme
involved in the early steps of the asparagine-linked (N-
linked) glycosylation pathway [5], and it is proposed that
impaired glycosylation of the muscle acetylcholine
receptor is a primary pathogenic mechanism in this form
of CMS [4]. A number of beneﬁcial treatments are
available for CMS, but appropriate treatment often
depends upon recognition of a myasthenic disorder,
knowledge of which gene is mutated, and an under-
standing of the underlying molecular mechanism [6]. Many
of the recently identiﬁed forms of CMS have a
predominantly proximal pattern of muscle weakness with
onset in childhood that can lead to a diagnosis of non-
speciﬁc myopathy, congenital myopathy, or congenital
muscular dystrophy prior to a deﬁnitive genetic diagnosis
[2]. Here we provide case reports for a large Iranian family
harbouring a previously unreported mutation in DPAGT1,
which both expands the described phenotype and may help
recognition of this disorder.
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2.1. Mutation analysis
No abnormal variants were detected in DOK7 or
GFPT1 which give rise to CMS with a predominantly
limb-girdle pattern of muscle weakness [7,3]. However,
subsequent bi-directional sanger sequence analysis of
PCR-ampliﬁed exonic regions and their ﬂanking
sequences in DNA from the proband (Case 2) detected a
previously unreported homozygous variant mutation in
exon5 of DPAGT1 (RefSeq: NM_001382.3) [5]. The
mutation, c.652C>T, results in the missense amino acid
substitution p.Arg218Trp. This newly identiﬁed mutation
was found to segregate with aﬀected members within this
large consanguineous family and is consistent with
recessive inheritance of CMS due to DPAGT1 mutations
[4] (Fig. 1A). The mutation is of a residue conserved in
mammals and zebraﬁsh (see Fig. 1B), and is predicted to
be damaging using the ‘Mutation Taster’ program
(http://www.mutationtaster.org/) [7]. The DPAGT1
c.652C>T variant is not present in 1000 Genomes Project
(http://browser.1000genomes.org) [8], the Exome variant
server (http://evs.gs.washington.edu/EVS/) [9], or the
dbSNP database (http://www.ncbi.nlm.nih.gov/projects/
SNP/) [10] consistent with designation as a pathogenic
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Fig. 1. A. Sanger sequencing of exon 5 of DPAGT1 showing co-segregation
within the pedigree. B. Conservation of the amino acid sequence of DPAGT1Case 1 (III-14) was a female from this large Iranian
family who was symptom-free up to school age, when she
presented with mild and ﬂuctuating proximal weakness of
lower extremities. Diagnosis of myasthenia gravis (MG)
was proposed when she was 7 years old and
administration of pyridostigmine, prednisone and
physical and occupational therapy resulted in partial
relief. She was able to perform almost normally in daily
activities for the next ﬁve years. Aged 15 she was
hospitalised with respiratory failure requiring ITU.
Increase in pyridostigmine and prednisolone led to partial
recovery with no history of hospitalisation for the
subsequent few years. The patient again required hospital
intervention aged 24, when her symptoms worsened
following a viral illness. At this time azathioprine was
added to her treatment regimen.
On examination, aged 25, she had severe weakness of
her proximal muscles. Deep tendon reﬂexes were reduced
throughout. Antibodies to the acetylcholine receptors
were not present. Electrophysiological testing revealed
abnormal decrement (up to 32%) on repetitive nerve
stimulation in keeping with a myasthenic disorder.
Myopathic potentials were seen on standard needle EMG
examination of all muscles tested and were most
prominent proximally. Fibrillations and positive sharp
waves were also detected on EMG. Nerve conduction
studies were normal. CT of the thymus was normal. A   II-7 
III-15III-13           III-14 
G    G    G    A    T
A    T    T    G    T    Y   G    G    G    A    T




of c.652C>T, (p.Arg218Trp), with disease in the four aﬀected individuals
between species in the region harbouring the mutations p.Arg218Trp.
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reduced number of muscle ﬁbres and replacement with
fat and connective tissue. The remaining muscle ﬁbre size
was variable and some demonstrated centralisation of
nuclei. No tubular aggregates were detected.
The withdrawal of prednisone and azathioprine and
symptomatic treatment with pyridostigmine resulted in
the patient regaining much of her normal strength.
However, the following year the patient died during a
further respiratory crisis.
Case 2 (III-9), a sister of case 1, at age 17 had sudden
onset of muscle cramps, severe fatigue and ﬂuctuating
ptosis. She was treated for myasthenia gravis and despite
thymectomy, no signiﬁcant improvement was seen. On
examination aged 28 she had mild proximal weakness of
her lower limbs. Deep tendon reﬂexes were normal. There
was signiﬁcant decrement in limb (40%) and facial
muscles (26%) on repetitive nerve stimulation. Needle
EMG examination showed a myopathic pattern with no
evidence of active denervation. A muscle biopsy of
Vastus lateralis muscle disclosed variation in ﬁbre size,
centralisation of nuclei and replacement of ﬁbres with
fatty tissue, without tubular aggregates. Serum creatine
kinase was normal. Tests for acetylcholine receptor
antibodies were negative.
Case 3 (III-10), a brother, ﬁrst presented with frequent
falls at the age of 3 years, and had a history of mild
weakness of extremities and muscle wasting. Muscle
cramps started aged 24. On examination aged 26 he had
mild weakness in proximal limbs, with sparing of ocular
muscles. Ankle reﬂexes were undetectable. Tests for
acetylcholine receptor antibodies were negative but
pyridostigmine resulted in symptomatic relief. On
repetitive nerve stimulation signiﬁcant decrement was
detected in the small muscles of the hands (29–33% in
ADM and APB), but not in facial muscles. A myopathic
pattern was seen on needle EMG examination of
proximal limb muscles.
Case 4 (III-12), a brother of the previous cases, ﬁrst
noticed weakness with diﬃculty climbing stairs aged
13 years, and was also noted at this time to have an
abnormal gait. On examination aged 34 he had mild
dysarthria, mild scoliosis, and lumbar hyperlordosis.
Ankle reﬂexes were reduced. There was mild weakness of
neck ﬂexor, arm abduction and extension and mild
weakness of hip extensors and abductors. There was also
mild fatiguable ptosis.
3. Discussion
We present a large consanguineous Iranian family in
which a limb-girdle myasthenia co-segregates with
mutations in the newly identiﬁed CMS-associated gene,
DPAGT1. The aﬀected family members expand the
phenotypic features associated with mutations in
DPAGT1 and highlight clinical characteristics that diﬀer
from the more common forms of CMS.Clinical features associated with myasthenic syndrome
due to mutations in DPAGT1 [4] include fatiguable
weakness that predominantly aﬀects proximal muscle
groups, spares ocular and facial muscles, and is responsive
to anticholinesterase medication. Onset is in childhood
usually delayed beyond infancy and aﬀected individuals
may have myopathic features associated with tubular
aggregates on muscle biopsy [4]. The cases described here
demonstrate a similar overall phenotype. They show a
more variable age of onset (between 3 and 17 years) than
previously reported and a marked contrast in disease
severity within a consanguineous family. None had mild
learning diﬃculties that can occur in this disorder. Case 1
suﬀered re-occurring life-threatening respiratory crises
which we have not previously seen in individuals with
DPAGT1 mutations. Marked ﬂuctuations in weakness are
noted and muscle cramps, which are a common feature of
DOK7 CMS [11,12] were prominent symptom for Cases 2
and 3. Repetitive nerve stimulation demonstrates marked
decrement and thus indicates impaired neuromuscular
transmission. However EMG revealed myopathic ﬁndings,
and in combination with the changes seen on the muscle
biopsies points to a myopathic component in the disorder.
Of note for Case 3, decrement was evident for the small
muscles of the hand which can show marked weakness in
DPAGT1 CMS, but was not seen in facial muscles that
tend to be spared. Surprisingly, tubular aggregates were
not identiﬁed in muscle biopsies from these cases,
indicating that their presence cannot be used as a deﬁnitive
marker for DPAGT1 CMS. A comparable situation is seen
in limb-girdle CMS due to GFPT1 mutations where
tubular aggregates are a common feature but they are not
always present [13].
As well as causing CMS, certain mutations in DPAGT1
have been reported to cause congenital disorder of
glycosylation type 1J (CDG type 1J) [14–17]. This is one of
a group of disorders caused by defects in the formation or
processing of glycoproteins or glycolipids [18]. Rare cases
of CDG type 1J due to DPAGT1 mutations have been
reported as a severe multisystem disorder with symptoms
including intractable seizures, congenital cataracts, mental
retardation, and developmental delay with microcephaly
[14,15], or with severe foetal hypokinesia with death in
infancy or early childhood [16,17].
The full phenotypic spectrum for mutations in DPAGT1
is likely to emerge with the advent of next generation
sequencing techniques, and as yet it is not clear why
symptoms in the patients we describe are largely
restricted to muscle and in particular to the
neuromuscular junction. Mutations in DPAGT1 are
thought to impair AChR subunit glycosylation leading to
reduced assembly and transport of the AChR into the
postsynaptic membrane, and thus reduced endplate
AChR number [4], which is consistent with a beneﬁcial
response to pyridostigmine. The relatively late onset of
DPAGT1 CMS, ﬂuctuating muscle weakness, response to
anticholinesterase medication and decremental response
472 K. Basiri et al. / Neuromuscular Disorders 23 (2013) 469–472on repetitive nerve stimulation may suggest seronegative
myasthenia gravis. Conversely, onset in childhood and
absence of ocular or facial weakness, and features on
muscle biopsy may suggest a non-speciﬁc myopathy
without a myasthenic component. It is likely there are
further patients with DPAGT1 CMS who currently carry
a diagnosis of seronegative myasthenia gravis or an
undeﬁned myopathic disorder. Recognition of these cases
should facilitate a genetic diagnosis and an appropriate
therapeutic strategy.
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